Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5705019 | 0.87 | PTGDR2 (0.49) | SLC2A1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL5705160 | 0.86 | SLC2A1 (0.52) | SCN9ASLC2A1HDAC3HDAC1HDAC2 | |
| SCHEMBL5705111 | 0.80 | SCN9A (0.52) | GPR119SCN9A | |
| SCHEMBL27322905 | 0.78 | SCN9A (0.50) | GPR119SCN9A | |
| Hydrochloric Acid SCHEMBL6133627 | 0.78 | HTR6 (0.53) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL5705187 | 0.77 | HTR6 (0.60) | GPR119SCN9A | |
| SCHEMBL558066 | 0.77 | SCN9A (0.61) | GPR119SCN9A | |
| SCHEMBL14181452 | 0.77 | SLC2A1 (0.57) | GPR119SLC2A1 | |
| SCHEMBL1570643 | 0.77 | HTR6 (0.58) | SCN9A | |
| SCHEMBL5705173 | 0.76 | SCN9A (0.46) | GPR119SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245540-A1 | New methods | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245540-A1 | New methods | TGFB1, TGFBR1, TGFB2 | GPR119 150/4885SCN9A 2148/4885SLC2A1 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.